Sort
261,768 grants matching “gene therapy”
Tumor suppressor vulnerability conferred by aneuploid loss of haploinsufficient metallothionein genes
$906,000Joe R Delaney · Medical University Of South Carolina · DP2 · FY2025 · CA
HIV-2 latency and its reversal
$905,874Athe M. Tsibris · Brigham And Women'S Hospital · R01 · FY2022 · AI
Modulating Stochastic Gene Expression for Cell-fate Control and Therapeutics
$905,866Leor S Weinberger · Autonomous Therapeutics, Inc. · R37 · FY2024 · AI
Genomics of Antibiotic Resistance in Bacterial Pathogens
$905,861Derrick Fouts · J. Craig Venter Institute, Inc. · U19 · FY2017 · AI
FIV Vectors for the Treatment of Hemophilia A
$905,804William C Raschke · Virogenics, Inc. · R44 · FY2010 · HL
Novel Extended Release Glaucoma Therapy for Once Daily Dosing
$905,799Monica M Jablonski · University Of Tennessee Health Sci Ctr · R24 · FY2024 · EY
Targeted Nanoparticles for Tempospatially Controlled Combination Chemotherapy
$905,712Robert S Langer · Massachusetts Institute Of Technology · U54 · FY2014 · CA
Clinical trials of patients with AIDS-related malignancies
$905,688Robert Yarchoan · Division Of Basic Sciences - Nci · Z01 · FY2008 · CA
Improving Mitral Compensation in Ischemic Regurgitation
$905,680Robert A Levine · Massachusetts General Hospital · R01 · FY2012 · HL
Genome instability in cancer: telomeres and DNA repair
$905,588Titia De Lange · Rockefeller University · R35 · FY2021 · CA
Exploiting synthetic lethality of hematopoietic lineage cells to develop novel ta
$905,570Kyle Russell Bonneau · Cellecta, Inc. · R44 · FY2012 · CA
Enhanced latency reversal and reservoir clearance in macaques
$905,505Ann M Chahroudi · Emory University · R37 · FY2021 · AI
Intracellular Innate Immune Receptors in Cancer Suppression and Immunotherapy
$905,500Jenny P.y. Ting · Univ Of North Carolina Chapel Hill · R35 · FY2022 · CA
Biomarker Prediction of Gleason Upgrading
$905,451Bruce J Trock · Johns Hopkins University · RC2 · FY2009 · CA
Subingual-parenteral Vaccination to Prevent Oral HIV Transmission in Infants
$905,447Kristina Abel · Univ Of North Carolina Chapel Hill · R01 · FY2020 · DE
Preclinical medication development for stimulant use disorder
$905,309Michael Baumann · National Institute On Drug Abuse · ZIA · FY2025 · DA
Genetic etiology of Amyotrophic Lateral Sclerosis
$905,307Bryan Traynor · National Institute On Aging · ZIA · FY2018 · AG
Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Crohn's disease
$905,290Kenneth Schultz · Trethera Corporation · R42 · FY2025 · DK
In vivo studies of neural system in zebrafish
$905,231Fumihito Ono · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2009 · AA
Genetic Analysis of the Multidrug Resistance Phenotype in Tumor Cells
$905,230Michael Gottesman · Division Of Basic Sciences - Nci · ZIA · FY2013 · CA
Interaction of Radiation, BRCA1/2, and Breast Cancer
$905,180Mount Sinai School Of Medicine Of Nyu · R01 · FY2003 · CA
Mapping Drug Resistance Genes in Plasmodium falciparum
$905,076Tim J Anderson · Texas Biomedical Research Institute · R01 · FY2025 · AI
A National iPS Cell Network with Deep Phenotyping for Translational Research
$905,076Darrell N. Kotton · Boston University Medical Campus · U01 · FY2016 · TR
Design and production of an automated electronic tissue stem cell counter
$905,064James L Sherley · Asymmetrex, Llc · R44 · FY2024 · HL
Targeting B-cell lymphoma with Leukothera-phase II
$905,040Benjamin A Belinka · Actinobac Biomed, Inc. · R42 · FY2014 · CA